{"id":64447,"date":"2026-04-20T09:22:47","date_gmt":"2026-04-20T09:22:47","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/64447\/"},"modified":"2026-04-20T09:22:47","modified_gmt":"2026-04-20T09:22:47","slug":"openai-teams-with-novo-nordisk-to-speed-prescription-drug-development-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/64447\/","title":{"rendered":"OpenAI Teams with Novo Nordisk to Speed Prescription Drug Development"},"content":{"rendered":"\n

Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors<\/a>.<\/p>\n

Anyone who moved to Hollywood with superstar dreams will sympathize. Now that its career as a movie-maker has stalled, OpenAI is pivoting to pharmaceuticals.<\/p>\n

Weeks after shuttering Sora, its consumer AI video generator, and amid a broader shift away from \u201cside quests\u201d and toward revenue-generating enterprise markets, OpenAI on Tuesday announced a partnership with Novo Nordisk to help the Wegovy-maker use AI to accelerate drug discovery. It\u2019s a sign everyone\u2019s favorite little AI firm is growing up \u2026 and feeling the heat from fast-charging rival Anthropic.<\/p>\n

Sign up for The Daily Upside at no cost for premium analysis on all your favorite stocks.<\/a><\/p>\n

READ ALSO:\u00a0US Automakers Poised to Benefit from Pentagon\u2019s Request for Manufacturing Support<\/a>\u00a0and\u00a0Amazon\u2019s $11B Globalstar Deal Fuels Project Leo\u2019s Pursuit of Starlink\u2019s Contrails<\/a><\/p>\n

Between Claude Code and cybersecurity tool Mythos, Anthropic has made a big splash this year in addressing critical (and practical) needs for enterprise firms. Meanwhile, OpenAI\u2019s massive lead in the consumer chatbot market is beginning to slip; according to the most recent data from Apptopia<\/a>, ChatGPT\u2019s US mobile chatbot market share fell for the fourth straight month in March, and now sits below 40%. Which is why it\u2019s seeking more lucrative career paths.<\/p>\n

Its Novo partnership comes after previous agreements with Moderna, Sanofi and Formation Bio to help accelerate drug development. Novo on Tuesday said the partnership will begin with programs integrating AI into R&D, manufacturing and commercial operations, though it will eventually involve full AI integration.<\/p>\n

Expect many more deals as OpenAI charts its long path to profitability:<\/p>\n

In a January episode of \u201cThe OpenAI Podcast,\u201d the company\u2019s in-house show, OpenAI CFO Sarah Friar floated a \u201clicensing model\u201d in which OpenAI would receive a portion of the sales<\/a> from drugs developed in part by its AI. Neither Novo Nordisk nor OpenAI responded to a request for comment on whether the deal announced Tuesday followed this structure.<\/p>\n

Earlier this month, OpenAI said that enterprise customers now account for 40% of its total revenue<\/a>, and it expects that business to achieve parity with consumer revenue by the end of the year.<\/p>\n

Defensive Position: OpenAI also launched GPT\u20115.4\u2011Cyber on Tuesday, its answer to Anthropic\u2019s Claude Mythos cybersecurity tool. In a matter of days since the launch of its pilot program, Mythos is already reshaping the cyber industry. Major Wall Street firms are employing a preview mode of the tool to inspect their cyber vulnerabilities, while Bloomberg reported Tuesday<\/a> that the US Treasury Department is now seeking access, too (never mind the US Defense Department blacklisting). It\u2019s easy to see why OpenAI leaped into the arena. And take it from this Angeleno: As far as backup plans for when big Hollywood dreams inevitably go awry, drug development and cybersecurity sound pretty good.<\/p>\n

This post first appeared on The Daily Upside<\/a>. To receive razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside<\/a> newsletter.<\/p>\n","protected":false},"excerpt":{"rendered":"Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built…\n","protected":false},"author":2,"featured_media":64448,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[272,19604],"class_list":["post-64447","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-novo-nordisk","tag-openai"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116436306782574996","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/64447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=64447"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/64447\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/64448"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=64447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=64447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=64447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}